Regenerative Medicine Firm Advances Multifaceted Pipeline
Source: Streetwise Reports  (11/26/19)
The company continues advancing its cell therapies and medical device. More >

Intercept Pharma Shares Rise on FDA Acceptance of NDA for Liver Fibrosis Treatment
Source: Streetwise Reports  (11/25/19)
Shares of Intercept Pharmaceuticals rose today after the company reported that the U.S. Food and Drug Administration accepted its NDA for obeticholic acid (OCA) for the treatment of liver fibrosis due to NASH and granted priority review status. More >

EyeGate Pharma Shares Looking Up on Pivotal PRK Ocular Bandage Gel Study Data
Source: Streetwise Reports  (11/22/19)
EyeGate Pharmaceuticals shares opened nearly 85% higher today after the company reported select topline data demonstrating that it met its primary endpoint in its cornea wound repairs pivotal photorefractive keratectomy study using the firm's Ocular Bandage Gel eye drop. More >

Hepion Pharma Shares Climb 50% Higher on NASH Liver Disease Treatment Results
Source: Streetwise Reports  (11/21/19)
Shares of Hepion Pharmaceuticals opened higher today after the company reported that its anti-fibrotic agent CRV431 prevented the development of liver cirrhosis in a highly aggressive, preclinical liver disease model. More >

Kiniksa Pharma Awarded FDA Breakthrough Therapy Status for Pericarditis Treatment Drug
Source: Streetwise Reports  (11/20/19)
Shares of Kiniksa Pharmaceuticals opened nearly 30% higher today after the firm reported that the FDA granted Breakthrough Therapy designation for Rilonacept for the treatment of recurrent pericarditis. More >

Myovant Sciences Shares Up 110% on Phase 3 Advanced Prostate Cancer Data
Source: Streetwise Reports  (11/19/19)
Shares of Myovant Sciences opened 120% higher today after the firm reported a 97% response rate in its Phase 3 HERO Study of oral Relugolix in men with advanced prostate cancer. In the study, Relugolix achieved all six key secondary endpoints and the firm expects to submit a New Drug Application in Q2/20. More >

Karuna Shares Jump 375% Higher on Phase 2 Acute Psychosis Treatment Trial Data
Source: Streetwise Reports  (11/18/19)
Shares of Karuna Therapeutics, which completed an IPO in July 2019, soared more than 375% higher today after the firm reported that its KarXT met primary endpoint in a phase 2 clinical trial of acute psychosis in patients with schizophrenia. More >

Sales of Antibiotic Alternative for Livestock Feed Accelerate in Asia
Source: Streetwise Reports  (11/15/19)
With antibiotic resistance a major health issue, the search is on for effective alternatives to replace antibiotics in livestock feed to promote growth. More >

Plus Therapeutics Shares Trade Higher on Q3 Earnings and Business Restructuring
Source: Streetwise Reports  (11/15/19)
Plus Therapeutics shares opened 25% higher today after the firm reported Q3/19 financial and business results. In the most recent quarter, the company completed the change of its name, relocated its headquarters to Austin, and raised $15 million for R&D and working capital. More >

Exicure's Collaboration with Allergan on Treating Hair Loss Disorders Sends Shares Higher
Source: Streetwise Reports  (11/14/19)
Shares of Exicure Inc. opened 30% higher today after the firm reported that it entered into a collaboration agreement with Allergan to discover and develop SNA-based treatments for hair loss disorders. The terms of the deal provide for a $25 million upfront payment to Exicure with the potential to grow to $750 million. More >

Biopharma Presents Data on Alcoholic Hepatitis Therapeutic at Liver Meeting
Source: Streetwise Reports  (11/13/19)
The company intends to follow up in 2020 with a Phase 2b clinical trial. More >

FDA Approval of Peanut Allergy Treatment Expected Next Year
Source: Streetwise Reports  (11/13/19)
The current status, catalysts and outlook for the immunotherapy are discussed in a ROTH Capital Partners report. More >

Clinical Trial Results for Alcoholic Hepatitis Drug Delivered in Webcast
Source: Streetwise Reports  (11/13/19)
The online presentation coincides with The Liver Meeting 2019, at which data also are shared. More >

Seachange in Mexico on Cannabis Could Benefit This Small Cap
Source: Clive Maund for Streetwise Reports  (11/13/19)
Technical analyst Clive Maund highlights a small-cap that may be poised to benefit from the recent Mexican Supreme Court decision on cannabis. More >

Iovance Biotherapeutics Shares Rise 12% on Updated Phase 2 Melanoma Study Results
Source: Streetwise Reports  (11/8/19)
Shares of Iovance Biotherapeutics traded 12% higher today after the firm reported updated clinical data from its phase 2 lifileucel metastatic melanoma trial. More >

Could There Finally Be an Effective Treatment for Alzheimer's Disease?
Source: Streetwise Reports  (11/6/19)
ProMIS' preclinical treatment could possibly outshine Biogen's candidate. More >

Aquestive Therapeutics Shares Up on Pipeline Update and Raised Full-Year 2019 Guidance
Source: Streetwise Reports  (11/6/19)
Aquestive Therapeutics shares traded 20% higher today after the firm reported Q3/19 earnings and raised its FY/19 guidance. The firm states it expects to complete its NDA for Libervant buccal film near the end of this month. More >

RedHill Biopharma Shares Rise 10% After Receiving FDA Approval for H. Pylori Treatment Drug Talicia
Source: Streetwise Reports  (11/4/19)
Shares of RedHill Biopharma Ltd. traded more than 10% higher today after the firm announced that the FDA has approved its Talicia delayed-release capsules for the treatment of H. pylori infection in adults. The firm plans to commence distribution by its U.S. sales force in Q1/20. More >

BeiGene Shares Up 35% on Amgen's $2.7 Billion Investment and China Partnership
Source: Streetwise Reports  (11/1/19)
Shares of BeiGene Ltd. traded 35% higher today to a new a 52-week intraday high after announcing a commercialization agreement for of XGEVA (denosumab), KYPROLIS (carfilzomib), and BLINCYTO (blinatumomab) with Amgen Inc. in China. As part of the partnership, Amgen will invest $2.7 billion in BeiGene for 20.5% equity ownership. More >

IVERIC bio Shares Double After Announcing Phase 2b AMD Topline Data
Source: Streetwise Reports  (10/28/19)
Shares of IVERIC bio opened nearly 100% higher today after reporting that it successfully met its primary endpoint in its Phase 2b age-related macular degeneration study for Zimura. More >

Biotech's Topline Phase 3 HER2-Positive Breast Cancer Data 'Impresses'
Source: Streetwise Reports  (10/23/19)
The results and commercial potential of the therapeutic are discussed in an H.C. Wainwright & Co. report. More >

Biotech Develops Antibodies Targeting TDP-43 in Neurodegenerative Diseases
Source: Streetwise Reports  (10/23/19)
These therapeutic candidates add to those already in the firm's pipeline. More >

Biogen Shares Rebound Strongly on Updated Phase 3 Alzheimer's Data and Q3 Earnings
Source: Streetwise Reports  (10/22/19)
Shares of Biogen Inc. opened nearly 39% higher today after the firm announced plans to submit a Biologics License Application to the FDA in early 2020 for its Alzheimer's drug aducanumab based on new analysis of larger datasets from two phase 3 studies. The company also announced Q3/19 earnings today. More >

Clinical Trial Starts for Biopharma's Antifungal in Cryptococcal Meningitis
Source: Streetwise Reports  (10/21/19)
The details of this study and a second one are outlined in a ROTH Capital Partners report. More >

Dermira's Phase 2b Atopic Dermatitis Trial Results Send Shares 25% Higher
Source: Streetwise Reports  (10/18/19)
Dermira shares traded higher today after the firm released positive data from its phase 2b study of lebrikizumab in patients with atopic dermatitis at the Las Vegas Fall Clinical Dermatology Conference. More >